复星医药子公司地舒单抗注射液获FDA药品注册批准

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received FDA approval for its biosimilar HLX14, which is intended for the treatment of osteoporosis in postmenopausal women at high risk of fractures [1] Group 1 - The biosimilar HLX14 is available in two specifications: 60mg/mL and 120mg/1.7mL [1] - HLX14 is developed to treat osteoporosis and other indications consistent with the reference drug's label [1]